Nasal Type Extranodal NK/T-Cell Lymphoma

Nasal Type Extranodal NK/T-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 25
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 16%
Top sponsor: Ruijin Hospital
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07502768	Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT)	recruiting	Phase 1 / Phase 2	107	Rong TaoOTHER	1	Jun 18, 2026	clinicaltrials
NCT07525466	Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)	recruiting	Phase 1 / Phase 2	25	Beijing Tongren HospitalOTHER	1	Apr 13, 2026